Exhibit 4.32
CONVERTIBLE NOTE AND WARRANT SUBSCRIPTION AGREEMENT
THIS CONVERTIBLE NOTE AND WARRANT SUBSCRIPTION AGREEMENT (this “Agreement”) is made this 25th day of June, 2026, among (i) SuperX AI Technology Limited (NASDAQ: SUPX) (the “Company”), a British Virgin Islands company, and (ii) the purchaser identified on its signature page to this Agreement (the “Purchaser”).
Purchase of Convertible Notes and Warrants
1. Subscription
1.1 The Company and the Purchaser are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Regulation S promulgated under the Securities Act of 1933, as amended (together with all of the rules and regulations promulgated thereunder, the “Securities Act”).
1.2 The Purchaser hereby agrees to subscribe for and purchase from the Company on the basis of the representations and warranties and subject to the terms and conditions set forth herein, senior unsecured convertible notes in the aggregate principal amount of USD 26,895,000 (corresponding to a conversion right of 3,300,000 Ordinary Shares at the Conversion Price) (the “Notes”), and warrants to purchase 1,100,000 ordinary shares, with no par value, of the Company (the “Warrants”, and together with the Notes, the “Securities”), for cash in US dollars (the “Subscription Proceeds”), in the amount set out on the Purchaser’s signature page hereto.
The Purchaser may transfer all or any portion of the Notes and Warrants (together, in the 3:1 ratio) before or after the Closing in accordance with this Agreement.
The Notes shall be issued at par, with a fixed conversion price of USD 8.15 per Ordinary Share (the “Conversion Price”), subject to standard anti-dilution adjustments for stock splits, stock dividends, combinations, recapitalizations and similar structural events (but not for subsequent equity financings). The Notes shall bear interest at a rate equal to the SOFR rate applicable on the date of this Agreement (or June 18, 2026, being 4.02163%) plus 2.2% per annum, calculated on a simple interest basis using the Actual/365 day count convention. Interest shall be payable in cash in arrears on the Maturity Date, any early redemption date or any conversion date (no periodic interest payments).
The term (the “Maturity Date”) of the Notes shall be the date that is twelve (12) months from the Closing Date.
The holder of the Notes shall have the right, exercisable on a one-time basis only (single exercise option) at any time prior to the Maturity Date, upon at least five (5) Business Days’ prior written notice to the Company, to convert all (but not less than all) of the outstanding principal amount of the Notes into Ordinary Shares at the Conversion Price. Upon conversion, accrued but unpaid interest on the converted principal shall also be paid in cash or, at the election of the Company and with the consent of the holder, added to the conversion or paid in Ordinary Shares (if agreed).
If the Notes are not converted or otherwise repaid prior to the Maturity Date, the Company shall, on the Maturity Date, repay the outstanding principal amount of the Notes together with all accrued but unpaid interest thereon in cash in immediately available funds.
The Warrants shall be issued to the Purchaser on the date upon which all of the Notes are converted into the Ordinary Shares in accordance with this Agreement (the “Warrant Issuance Date”) in the form attached as Exhibit C (or substantially similar form agreed by the parties), evidencing the Company’s obligation to issue the Warrants on the Warrant Issuance Date pursuant to Section 1.2 of this Agreement, and shall be exercisable at an exercise price of USD 8.15 per Ordinary Share (subject to adjustment on the same basis as the Conversion Price), for a period of two (2) years from the Warrant Issuance Date (the “Warrant Exercisable Period”). The Warrants shall be exercisable up to a maximum of three (3) times in the aggregate during the Warrant Exercisable Period, and shall be exercisable solely by cash payment via wire transfer of immediately available funds to the absolute exclusion of any cashless or net exercise mechanisms. The number of Warrants shall at all times equal one-third (1/3) of the aggregate number of Ordinary Shares issuable upon conversion of the Notes (the “Warrant Coverage Ratio”). The figure of 1,100,000 Warrants reflects the Warrant Coverage Ratio calculated on the basis of conversion of the initial aggregate principal amount of the Notes (USD 26,895,000) at the Conversion Price (being 3,300,000 Ordinary Shares). If and to the extent the aggregate number of Ordinary Shares issuable upon conversion of the Notes increases (including as a result of any accrued and unpaid interest being added to the principal or conversion amount of the Notes pursuant to Section 1.2), the number of Warrants shall increase proportionately so as to maintain the Warrant Coverage Ratio, and the Company shall reserve a corresponding number of additional Ordinary Shares pursuant to Section 10.5.
The Warrants, the Notes and any rights or obligations thereunder shall not be assigned, transferred, pledged, or otherwise disposed of (including, without limitation, any pro-rata distribution or in-kind distribution by the Purchaser to its partners, limited partners, or affiliates, which shall be deemed a “Transfer”) by the holder thereof without the prior written consent of the Company, which consent shall not be unreasonably withheld, delayed, or conditioned. Any permitted transferee shall expressly assume all obligations of the Purchaser hereunder and shall contain a beneficial ownership limitation of 9.99% of the outstanding Ordinary Shares (as set forth in more detail in the form of Warrant). Upon any transfer of all or any portion of the Notes, a number of Warrants (or, prior to the Warrant Issuance Date, the corresponding right to receive Warrants) equal to one-third (1/3) of the number of Ordinary Shares then issuable upon conversion of the Notes so transferred shall be transferred together with, and in the same proportion as, such Notes, so as to maintain the 3:1 ratio between the Ordinary Shares issuable upon conversion of the Notes and the Warrants. Notwithstanding the foregoing, the Purchaser may, without the prior written consent of the Company, assign, transfer, pledge or otherwise dispose of (including by way of any pro-rata or in-kind distribution to any of its partners or limited partners that are Affiliates of the Purchaser) the Notes, the Warrants and any rights or obligations thereunder, in whole or in part, to one or more of its Affiliates, provided that each such Affiliate transferee executes a written instrument assuming the obligations of the Purchaser hereunder and remains subject to the 9.99% beneficial ownership limitation. Any assignment, transfer, pledge, disposition or in-kind distribution to a person that is not an Affiliate of the Purchaser shall require the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed).
| 2 |
For the purposes of this Agreement, “Affiliate” means, with respect to any person, any other person that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such first person; and “control” (including the terms “controlling,” “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract or otherwise. References in this Agreement to “affiliate” or “affiliates” (whether or not capitalized) shall be construed as references to an Affiliate or Affiliates as defined in this Section.
The Notes shall be senior unsecured obligations of the Company, ranking pari passu with all other senior unsecured indebtedness of the Company.
2. Payment
2.1 The Subscription Proceeds payable by the Purchaser shall be paid by wire transfer to the following bank account of the Company.
Title of the Account:
Account #:
Beneficiary Bank:
Swift Code:
Bank Address:
3. Deliveries at or Prior to Closing
3.1 The Company shall deliver to the Purchaser the following closing deliverables prior to or at the Closing:
| (a) | a counterpart of this Agreement, duly executed by an authorized signatory of the Company; |
| (b) | the Notes in the principal amount set forth on the signature page hereto, duly executed by an authorized signatory of the Company (in certificated form or book-entry notation, as agreed); |
| (c) | a certificate or evidence of electronic book entry representing the underlying Ordinary Shares issuable upon conversion or exercise, if applicable at Closing (or reservation confirmation); |
| (d) | the opinion of Ogier or other reputable law firm (as the case may be), as the Company’s British Virgin Islands counsel, dated as of the Closing Date, in customary form and substance to be reasonably agreed upon with the Purchaser and addressing such legal matters as substantially set forth in Schedule I attached hereto; |
| 3 |
| (e) | the opinion of Ortoli Rosenstadt LLP or other reputable law firm (as the case may be), as the Company’s U.S. counsel, dated as of the Closing Date, in customary form and substance to be reasonably agreed upon with the Purchaser and addressing such legal matters as substantially set forth in Schedule II attached hereto; |
| (f) | a certificate duly signed by an authorized officer of the Company, dated as of the Closing Date, certifying that the conditions specified in Sections 5.2(b) to (h) of this Agreement have been fulfilled; and |
| (g) | a certificate duly signed by the secretary of the Company, dated as of the Closing Date, certifying (i) the current-effective Memorandum and Articles of Association of the Company (the “M&AA”) and (ii) resolutions of the Company’s Board of Directors approving this Agreement and the transactions contemplated by this Agreement, including, without limitation, the issuance of the Notes, the Warrants and the Ordinary Shares issuable upon conversion of the Notes or exercise of the Warrants (the “Underlying Shares”). |
3.2 The Purchaser shall deliver to the Company the following closing deliverables prior to or at the Closing:
| (a) | a counterpart of this Agreement, duly executed by an authorized signatory of the Purchaser; and |
| (b) | payment of the Subscription Proceeds payable by the Purchaser in accordance with the wire instructions set forth in Section 2.1 above. |
4. Closing
4.1 Subject to the satisfaction or waiver of the conditions set forth in Section 5 of this Agreement, the closing of the purchase and sale of the Notes and Warrants (the “Closing” and the date on which the Closing occurs, the “Closing Date”) shall occur remotely via the exchange of documents and signatures at such time as agreed to by the Company and the Purchaser, and in no event later than the twentieth Business Day (where “Business Day” means any day other than a Saturday, Sunday or any other day on which commercial banks in The City of New York, Hong Kong or Singapore are authorized or required by law, regulation or executive order to close) after the date of this Agreement unless otherwise agreed by the Company and the Purchaser. At the Closing, the Notes being purchased by the Purchaser shall be issued and registered in the name of the Purchaser, or in such nominee name(s) as designated by the Purchaser, representing the principal amount of Notes to be purchased by the Purchaser at the Closing as set forth on the Purchaser’s signature page hereto, with the Warrants to be issued to the Purchaser on the Warrant Issuance Date in accordance with Section 1.2, in each case against payment to the Company of the Subscription Proceeds therefor in full, by wire transfer to the Company of immediately available funds, at or prior to the Closing, in accordance with wire instructions set forth in Section 2.1 above.
| 4 |
5. Conditions to Closing
5.1 The obligation of the Company to consummate the transactions to be consummated at the Closing, and to issue and sell to the Purchaser the Notes and Warrants to be purchased by it at the Closing pursuant to this Agreement, is subject to the satisfaction or waiver in writing of the following conditions precedent:
| (a) | delivery by the Purchaser of the closing deliverables as set forth in Section 3.2. |
| (b) | that all of the representations and warranties of the Purchaser made in this Agreement shall be true and accurate in all material respects on each day from the date of this Agreement and to the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date; |
| (c) | that all of the obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed; and |
| (d) | that the Company shall have received the Subscription Proceeds payable by the Purchaser. |
5.2 The obligations of the Purchaser to consummate the transactions to be consummated at the Closing, and to purchase and pay for the Notes and Warrants being purchased by it at the Closing pursuant to this Agreement, are subject to the satisfaction or waiver in writing of the following conditions precedent:
| (a) | delivery by the Company of the closing deliverables as set forth in Section 3.1. |
| (b) | that the representations and warranties of the Company contained herein shall be true and correct in all material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, on each day from the date of this Agreement and to the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date, except for those representations and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date; |
| (c) | that all of the obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; |
| (d) | that the purchase of and payment for the Notes and Warrants by the Purchaser shall not be prohibited or enjoined by any law or governmental or court order or regulation and no such prohibition shall have been threatened in writing; |
| 5 |
| (e) | that the Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the purchase and sale of the Notes and Warrants, all of which shall be in full force and effect; |
| (f) | that the Company shall have furnished all required materials to the transfer agent of the Company to reflect the reservation or issuance of the Underlying Shares to be issued upon conversion or exercise; |
| (g) | that since the date of this Agreement, no event or series of events shall have occurred that has had or would reasonably be expected to have a Material Adverse Effect; and |
| (h) | that no stop order or suspension of trading shall have been imposed by Nasdaq Stock Market (“Nasdaq”), the SEC or any other governmental or regulatory body with respect to public trading in the Ordinary Shares as of the Closing Date. The Ordinary Shares shall be listed on Nasdaq and shall not have been suspended, as of the Closing Date, by the SEC or Nasdaq from trading thereon nor shall suspension by the SEC or Nasdaq have been threatened, as of the Closing Date, in writing by the SEC or Nasdaq; and the Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Underlying Shares and Nasdaq shall have raised no objection to such notice and the transactions contemplated hereby. |
6. Representations, Warranties, Acknowledgements and Covenants of the Purchaser
6.1 The Purchaser hereby acknowledges and agrees as of the date hereof and as of the Closing Date that:
| (a) | none of the Securities have been registered under the Securities Act, or under any state securities or “blue sky” laws of any state of the United States or any other jurisdiction; |
| (b) | the decision to execute this Agreement and acquire the Securities hereunder has not been based upon any oral or written representation (other than representations set out in this Agreement) as to fact or otherwise made by or on behalf of the Company; |
| (c) | there are risks associated with an investment in the Company and the Securities, including, but not limited to those set forth in Company’s latest annual report on Form 20-F incorporated herein by reference; |
| (d) | it has received all the information it considers necessary or appropriate for purposes of deciding whether to purchase the Securities. The Purchaser further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the Securities and regarding the business, properties, prospects and financial condition of the Company, and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to it or to which it had access; |
| 6 |
| (e) | it has been advised to consult its own legal, tax and other advisors with respect to the merits and risks of an investment in the Securities and with respect to applicable resale restrictions; |
| (f) | it understands that the Company is making no representations and warranties regarding tax consequences for its investment in the Securities or the securities law of the home or residential jurisdiction of any Purchaser. |
6.2 The Purchaser hereby represents and warrants to, and covenants with, the Company (which representations, warranties and covenants shall survive the Closing) as of the date hereof and as of the Closing Date that:
| (a) | it has the legal capacity and competence to enter into and execute this Agreement and to take all actions required hereby and, if the Purchaser is a corporation, it is duly incorporated and validly existing under the laws of its jurisdiction of incorporation and all necessary approvals by its directors, shareholders and others have been obtained to authorize execution and performance of this Agreement on its behalf; |
| (b) | the entering into of this Agreement and the transactions contemplated hereby do not result in the violation of any of the terms and provisions of any law or regulation applicable to the Purchaser or of any agreement, written or oral, to which the Purchaser may be a party or by which the Purchaser is bound, except as would not, individually or in the aggregate, be reasonably expected to materially delay or hinder the ability of the Purchaser to perform its obligations under this Agreement; |
| (c) | the Purchaser has duly executed and delivered this Agreement and it constitutes a valid and binding agreement of the Purchaser enforceable against the Purchaser in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies; |
| (d) | the Purchaser is not a “U.S. Person” as defined in Rule 902 under the Securities Act and is resident in the jurisdiction set out under the heading “Name and Address of Purchaser” on the signature page of this Agreement; |
| (e) | At the time Purchaser executed and delivered this Agreement, Purchaser was outside the United States and is outside of the United States as of the date of the execution and delivery of this Agreement; |
| (f) | Purchaser is acquiring the Securities for its own account and not on behalf of any U.S. person, and the sale has not been pre-arranged with a purchaser in the United States; |
| 7 |
| (g) | Purchaser represents and warrants and hereby agrees that all offers and sales of any of the Securities prior to the expiration of the applicable Restricted Period (as defined below) shall only be made in compliance with the safe harbor contained in Regulation S, pursuant to registration of the Securities under the Securities Act or pursuant to an exemption from registration, and all offers and sales after the applicable Restricted Period shall be made only pursuant to such a registration or to such exemption from registration. For these purposes, “Restricted Period” means: (i) with respect to the Notes and the Ordinary Shares issued or issuable upon conversion of the Notes, the period commencing on the Closing Date and ending six (6) months thereafter, it being acknowledged that, pursuant to Rule 144(d)(3)(ii) under the Securities Act, the holding period for such conversion shares shall be deemed to have commenced on the date of issuance of the Notes (the Closing Date), as the Notes are convertible without payment of additional consideration; and (ii) with respect to the Warrants and the Ordinary Shares issued or issuable upon exercise of the Warrants, the period commencing on the date of exercise of the relevant Warrants (and payment of the exercise price therefor) and ending six (6) months thereafter, such Warrant shares not being eligible for tacking under Rule 144(d) by reason of the cash exercise of the Warrants; |
| (h) | the Purchaser (i) has such knowledge and experience in business matters as to be capable of evaluating the merits and risks of its prospective investment in the Securities; and (ii) has the ability to bear the economic risks of its prospective investment and can afford the complete loss of such investment; |
| (i) | the Purchaser is not aware of any advertisement of any of the Securities and is not acquiring any of the Securities as a result of any form of general solicitation or general advertising including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or broadcast over radio or television, or any seminar or meeting whose attendees have been invited by general solicitation or general advertising; |
| (j) | no person has made any written or oral representations to the Purchaser: |
| (i) | that any person will resell or repurchase any of the Securities; |
| (ii) | that any person will refund the purchase price of any of the Securities; or |
| (iii) | as to the future price or value of any of the Securities. |
6.3 Between the date of this Agreement and the Closing, the Purchaser shall notify the Company if any of the above representations and warranties ceases to be true.
6.4 The Purchaser acknowledges that the representations and warranties contained herein are made by it with the intention that they may be relied upon by the Company and its legal counsel in determining the Purchaser’s eligibility to purchase the Securities for which it is subscribing under applicable securities legislation.
| 8 |
7. Representations and Warranties of the Company
7.1 The Company acknowledges and agrees that the Purchaser is entitled to rely upon the representations and warranties of the Company, contained in this Agreement and further acknowledges that the Purchaser will be relying upon such representations and warranties in purchasing the Securities. The Company represents and warrants as follows as of the date hereof and as of the Closing Date:
| (a) | The Company is duly incorporated, validly existing and in good standing under the laws of the British Virgin Islands. |
| (b) | The Company has the requisite power and authority to own and use its properties and assets and to carry on its business as currently conducted and described in the SEC Reports. The “SEC Reports” means (a) the Company’s most recently filed Annual Report on Form 20-F and (b) all Reports on Form 6-K furnished by the Company following the end of the most recent fiscal year for which an Annual Report on Form 20-F has been filed and prior to the Closing Date, together in each case with any documents incorporated by reference therein or exhibits thereto. |
| (c) | The Company is not in violation or default of any of the provisions of its M&AA. The Company is duly qualified to conduct its business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not reasonably be expected to result in (i) a material adverse effect on the legality, validity or enforceability of this Agreement, (ii) a material adverse effect on the results of operations, assets, business or financial condition of the Company, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis its obligations under this Agreement (any of (i), (ii) or (iii) being hereafter referred to as a “Material Adverse Effect”), and no proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. |
| (d) | The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement, including the issuance and sale of the Notes, the Warrants and the Underlying Shares, and to carry out its obligations hereunder. All action on the part of the Company, its officers, directors and shareholders, if necessary or required under the applicable laws, regulations or Nasdaq Rules, for the authorization of the Notes, Warrants and Underlying Shares, the authorization, execution, delivery and performance of this Agreement and the consummation of the transactions contemplated herein has been taken. |
| (e) | Upon delivery, this Agreement will have been duly executed by the Company and will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with their terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies. |
| 9 |
| (f) | The execution and delivery of this Agreement and the performance by the Company of the obligations imposed on it in this Agreement, including the issuance and sale of the Notes, Warrants and Underlying Shares, will not (i) conflict with or violate any provision of the M&AA or other organizational or charter documents of the Company, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any material agreement, credit facility, debt or other instrument or other agreement to which the Company is a party or by which any material property or material asset of the Company is bound, or (iii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company is subject, or by which any property or asset of the Company is bound, except, in each case, as could not reasonably be expected to result in a Material Adverse Effect. |
| (g) | The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other person in connection with the execution, delivery and performance by the Company of this Agreement, including the issuance of the Notes, Warrants and Underlying Shares, other than filings required under applicable securities laws which either have been made or will be made by the Company before the applicable deadline under the applicable laws and regulations for such filing. |
| (h) | The Notes, Warrants and Underlying Shares being purchased or issuable hereunder have been duly and validly authorized and, upon issuance pursuant to the terms of this Agreement against full payment therefor in accordance with the terms of this Agreement (or upon conversion or exercise), will be duly and validly issued, fully paid and non-assessable (in the case of Underlying Shares) and will be issued free and clear of any liens or other restrictions (other than those as provided in this Agreement or restrictions on transfer under applicable state and federal securities laws), and the holder of the Underlying Shares shall be entitled to all rights accorded to a holder of Ordinary Shares. The issuance and delivery of the Notes and Warrants does not, and the conversion of the Notes or exercise in full of the Warrants and the issuance and delivery of the Underlying Shares thereupon will not, (a) obligate the Company to offer to issue, or issue, Ordinary Shares or other securities to any Person (other than the Purchaser) pursuant to any preemptive rights, rights of first refusal, rights of participation or similar rights, or (b) result in any adjustment (automatic, at the election of any Person or otherwise) of the exercise, conversion, exchange or reset price under, or any other anti-dilution adjustment pursuant to, any securities of the Company currently outstanding as of the Closing Date (other than as contemplated by the anti-dilution provisions of the Notes and Warrants). Subject to the accuracy of the representations and warranties made by the Purchaser in Section 6, the offer and sale of the Notes and Warrants to the Purchaser is, and will be, (i) exempt from the registration and prospectus delivery requirements of the Securities Act and (ii) exempt from (or otherwise not subject to) the registration, qualification and prospectus delivery requirements of applicable securities laws of the states of the United States. |
The Company shall maintain a sufficient reservation of 4,400,000 Ordinary Shares (comprising 3,300,000 shares for Note conversion and 1,100,000 shares for Warrant exercise).
| (i) | The Company further makes such representations and warrants to the Purchaser as set forth in Schedule III attached hereto, and for the avoidance of doubt, the provisions of Schedule III shall be deemed part of this Section 7.1. |
| 8. | Legending of Subject Securities. |
8.1 The Purchaser hereby acknowledges that upon the issuance thereof, and until such time as the same is no longer required under the applicable securities laws and regulations, any certificates representing the Notes, Warrants or Ordinary Shares may bear a restrictive legend pursuant to applicable laws and may include language substantially similar to the below:
“THE SECURITIES REPRESENTED HEREBY HAVE BEEN OFFERED IN AN OFFSHORE TRANSACTION TO A PERSON WHO IS NOT A U.S. PERSON (AS DEFINED HEREIN) PURSUANT TO REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE”SECURITIES ACT”). NONE OF THE SECURITIES REPRESENTED HEREBY HAVE BEEN REGISTERED UNDER THE SECURITIES ACT, OR ANY U.S. STATE SECURITIES LAWS, AND, UNLESS SO REGISTERED, MAY NOT BE OFFERED OR SOLD, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES (AS DEFINED HEREIN) OR TO U.S. PERSONS EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S UNDER THE SECURITIES ACT, PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN EACH CASE ONLY IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. IN ADDITION, HEDGING TRANSACTIONS INVOLVING THE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT. “UNITED STATES” AND “U.S. PERSON” ARE AS DEFINED BY REGULATION S UNDER THE SECURITIES ACT.”
| 10 |
8.2 In connection with any sale, assignment, transfer or other disposition of the Ordinary Shares or Warrant Shares by a Purchaser pursuant to Rule 144 or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable securities and upon compliance by the Purchaser with the requirements of this Agreement, the Purchaser shall instruct the Company’s transfer agent (the “Transfer Agent”) in writing to remove any restrictive legends. The Purchaser shall deliver such written instruction, in the form of an email (the “Legend Removal Notice”), to the Transfer Agent’s email address provided by the Company. The Company shall take (a) all necessary actions to cause the Transfer Agent to, upon receipt of the Legend Removal Notice and a selling shareholder representation letter in the form attached hereto as Exhibit A, as soon as reasonably practicable in accordance with applicable law and its customary procedures, remove any restrictive legends related to the book-entry account holding such securities and make a new, unlegended entry for such book-entry securities sold or disposed of, and (b) provide all necessary cooperation for such legend removal, including the timely delivery of the company certificate substantially in the form attached hereto as Exhibit B and other customary certificates and other documents that may be reasonably requested by the Purchaser or the Transfer Agent. If the Transfer Agent fails to respond to the Purchaser’s Legend Removal Notice within 24 hours following the delivery of such notice by the Purchaser, the Purchaser shall have the right to request the Company to, and the Company shall upon such request promptly instruct the Transfer Agent to complete the legend removal requests specified in the Legend Removal Notice within two business days following the initial delivery of the Legend Removal Notice. The Company shall be responsible for the fees of the Company’s transfer agent and the Purchaser shall be responsible for its own legal counsel and any costs associated with such legend removal, including obtaining and delivering any legal opinion required in connection with a sale or transfer of the Ordinary Shares or Warrant Shares pursuant to Rule 144; provided, however, that any delay, failure or omission by the Transfer Agent to complete such legend removal shall not constitute a breach or default by the Company under this Agreement, provided that the Company has (i) instructed the Transfer Agent to remove the applicable restrictive legends within the time period set forth in this Section
8.2 and (ii) delivered, or caused to be delivered, to the Transfer Agent the company certificate substantially in the form of Exhibit B and all other certificates, opinions and documents reasonably required to effect such legend removal.
8.3 Subject to delivery by the Purchaser to the Transfer Agent of the Legend Removal Notice, upon the earliest of such time as the Ordinary Shares or Warrant Shares (i) have been sold under the Securities Act pursuant to an effective registration statement; (ii) have been sold pursuant to Rule 144, or (iii) are eligible for resale under Rule 144(b)(1) without the requirement for the Company to be in compliance with the current public information requirements under Rule 144(c)(1) (or any successor provision), the Company shall, in accordance with the provisions of this Section 8.3 and as soon as reasonably practicable following any request therefor from a Purchaser, deliver to the transfer agent of the Company irrevocable instructions that such transfer agent shall make a new, unlegended entry for such book entry securities.
9. Costs
9.1 Unless otherwise provided in this Agreement, the Purchaser acknowledges and agrees that all costs and expenses incurred by the Purchaser (including any fees and disbursements of any special counsel retained by the Purchaser) relating to the purchase of the Securities shall be borne by the Purchaser.
| 11 |
10. Covenants
10.1 Further Assurances. Each party agrees to cooperate with each other and their respective officers, employees, attorneys, accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate the intents and purposes of this Agreement, subject to the terms and conditions of this Agreement and compliance with applicable law, including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other parties hereto in complying with the terms of this Agreement.
10.2 Listing. The Company shall use reasonable best efforts to maintain the listing and trading of its Ordinary Shares on the Nasdaq and, in accordance therewith, will use reasonable best efforts to comply in all material respects with the Company’s reporting, filing and other obligations under the rules and regulations of Nasdaq. The Company shall use reasonable best efforts to cause the Underlying Shares to be approved for listing on Nasdaq, subject to official notice of issuance, prior to or promptly following the Closing.
10.3 Disclosure of Transactions. On or before the fourth (4th) Business Day following the Closing Date or such earlier date as the Company may elect, the Company shall file with the SEC a Report on Form 6-K disclosing all material terms of the transactions contemplated by this Agreement and all material non-public information regarding the Company or its subsidiaries provided to the Purchaser by the Company or its representatives in connection with the transactions contemplated by this Agreement, with a form of this Agreement attached as exhibits to such 6-K. Notwithstanding anything in this Agreement to the contrary, the Company shall not publicly disclose the name of the Purchaser or any of its affiliates or advisors, or include the name of the Purchaser or any of its general partner, limited partners, their respective affiliates or advisors in any press release or filing with the SEC or any regulatory agency, without the prior written consent of the Purchaser, except (i) as required by the federal securities law in connection with the filing of the final transaction agreements with the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii) to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq, in each case of (i) or (ii), the Company shall promptly provide the draft disclosure or filing to the Purchaser in advance, give the Purchaser reasonable time to review such disclosure or filing, and consider in good faith of any comments that the Purchaser may have.
10.4 Integration; Regulation S Compliance. The Company shall not, and shall use its commercially reasonable efforts to ensure that no affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that will be integrated with the offer or sale of the Notes and Warrants being sold under this Agreement in a manner that would require the registration under the Securities Act of the sale of such securities to the Purchaser, or that will be integrated with the offer or sale of such securities for purposes of the rules and regulations of Nasdaq such that it would require shareholder approval prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction, or there are any applicable exemptions to the requirement for shareholder approval, including the home country exemption. With respect to those Securities sold pursuant to this Agreement in reliance upon Regulation S, (i) none of the Company, its affiliates or any person acting on its or their behalf will engage in any directed selling efforts within the meaning of Regulation S and (ii) each of the Company and its affiliates and any person acting on its or their behalf will comply with the offering restrictions set forth in Regulation S.
| 12 |
10.5 Reservation of Ordinary Shares. As of the date of this Agreement and until the expiration, conversion, or exercise in full of the Notes and Warrants,, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights or similar rights of participation, a sufficient number of Ordinary Shares, which shall in no event be less than an aggregate of 4,400,000 Ordinary Shares (comprising 3,300,000 shares for Note conversion and 1,100,000 shares for Warrant exercise), for the purpose of enabling the Company to issue the Underlying Shares that are issuable upon conversion of the Notes or exercise of the Warrants. The Company covenants that such reserved shares shall be protected from and shall not be diluted, displaced, or preempted by any subsequent equity financings, stock issuances, or corporate reorganizations.
10.6 Use of Proceeds. The Company shall use the net proceeds from the transactions contemplated by this Agreement only for lawful purposes and shall not, directly or indirectly, use such proceeds, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture or other Person, in any manner that would (or would be reasonably likely to): (a) constitute a violation of any of the anti-bribery, anti-money laundering, export control or economic sanctions laws referenced in Section 19 of Schedule III (the “Specified Laws”); or (b) cause any representation or warranty set forth in Section 19 of Schedule III to be untrue or inaccurate as if made at the time of such use. Without limiting the foregoing, the Company shall not use such proceeds to fund, finance, facilitate or support any (i) unlawful payment, gift, promise or offer to any government official or other Person in violation of the Specified Laws, (ii) transaction with, or for the benefit of, any Person that is the subject of sanctions administered by the U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”) (a “Sanctioned Person”), or (iii) transaction in, or involving the government of, any country or territory that is the subject of comprehensive OFAC sanctions (a “Sanctioned Country”), in each case, to the extent prohibited by the Specified Laws.
10.7 Rule 144. With a view to making available to the Purchaser the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Purchaser to sell Ordinary Shares to the public without registration, the Company covenants and agrees to, until the earlier of (A) six months after such date as all of the Ordinary Shares held by the Purchaser (including all of the Underlying Shares that may be acquired by the Purchaser upon conversion of the Notes and/or exercise of the Warrants, in each case whether or not then issued) may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect or (B) such date as the Purchaser no longer holds any Notes, Warrants or Underlying Shares: (i) make and keep adequate current public information available, as those terms are understood and defined in Rule 144; (ii) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; and (iii) furnish electronically to the Purchaser upon its reasonable written request, as long as the Purchaser holds any Notes, Warrants or Underlying Shares, (A) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act, (B) a copy of or electronic access to the Company’s most recent Annual Report on Form 20-F or interim financial statements on Form 6-K, and (C) such other publicly available information as may be reasonably requested in order to avail the Purchaser of any rule or regulation of the SEC that permits the selling of any such Ordinary Shares without registration.
| 13 |
10.8 Notice of Certain Events. From the date of this Agreement until the Closing (or until the Note is fully repaid or converted), the Company shall give written notice to the Purchaser within one (1) Business Day after a director or executive officer of the Company becomes aware of (i) any breach or anticipated breach by the Company of any representation or warranty, covenant or any other terms of under or in connection with this Agreement, and (ii) any event, change or development (including, without limitation, any actual or threatened (in writing) suit, action, proceeding, arbitration, claim, investigation, charge, complaint or inquiry by or before any court or arbitration, governmental authority, regulator or Nasdaq) that has had, or would reasonably be expected to have, a Material Adverse Effect. The delivery of any such notice pursuant to this Section 10.8 shall not be deemed to amend or supplement this Agreement, the Schedules hereto or any representation or warranty.
10.9 Most Favored Nation. From the date of this Agreement until the date on which no Notes remain outstanding, if the Company issues or sells to any other investor any convertible notes, debentures, warrants or other securities convertible into or exercisable for Ordinary Shares on terms (including as to conversion or exercise price, interest rate, maturity, anti-dilution protection, redemption, registration rights or ranking) that, taken as a whole, are more favorable to such investor than the terms of the Securities are to the Purchaser, then the Company shall promptly notify the Purchaser in writing of such terms and, at the Purchaser’s election, this Agreement shall be deemed amended to afford the Purchaser the benefit of such more favorable terms. This Section 10.9 shall not apply to issuances under any equity incentive plan approved by the Company’s board of directors or to bona fide commercial bank or equipment financings that are not convertible into Ordinary Shares.
11. Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury
11.1 This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to choice of laws or conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction. The Company and the Purchaser hereby irrevocably and unconditionally:
| (a) | submits for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated hereby, to the general jurisdiction of any state court or United States Federal court sitting in the Borough of Manhattan, City of New York in the State of New York; |
| (b) | consents that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to the venue of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not to plead or claim the same to the extent permitted by applicable law; |
| (c) | agrees that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing clause (i) are not available despite the intentions of the parties hereto; |
| (d) | agrees that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of any jurisdiction to which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified herein or as otherwise permitted by law; |
| (e) | agrees that to the extent that such party has or hereafter may acquire any immunity (whether on the basis of sovereignty or otherwise) from jurisdiction of any court or from any legal process with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement, to the extent permitted by law including, without limitation, any immunity pursuant to the United States Foreign Sovereign Immunities Act of 1976, as amended; and |
| (f) | irrevocably and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement. |
12. Confidentiality
12.1 The Purchaser covenants that until such time as the transactions contemplated by this Agreement and any material non-public information provided to the Purchaser are publicly disclosed by the Company, such Purchaser will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction), other than to the Purchaser’s general partner, limited partners, their respective affiliates, directors and officers of the foregoing entities, outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law.
12.2 The Company may request from the Purchaser such reasonable and customary additional information as the Company may deem necessary to evaluate the eligibility of the Purchaser to acquire the securities under this Agreement. The Company agrees to keep any such information provided by the Purchaser confidential, except to the extent such disclosure is required by law, at the request of the staff of the SEC or regulatory agency or under the regulations of Nasdaq, in each case the Company shall promptly provide the draft disclosure to the Purchaser in advance, give the Purchaser reasonable time to review such disclosure, and consider in good faith of any comments that the Purchaser may have.
| 14 |
13. Survival
13.1 Unless otherwise terminated under Section 22.1 hereof, this Agreement, including without limitation the representations, warranties and covenants contained herein, shall survive and continue in full force and effect and be binding upon the parties hereto notwithstanding the completion of the purchase of the Securities by the Purchaser pursuant hereto; provided, however, that the representations and warranties of the Company contained in Section 7 and Schedule III herein and of the Purchaser contained in Section 6 herein shall survive the Closing until the date that is eighteen (18) months after the Closing Date, after which they shall terminate and expire except with respect to any claim as to which written notice has been delivered prior to such expiration.
14. Assignment
14.1 None of the parties may assign its rights or obligations under this Agreement or designate another person (i) to perform all or part of its obligations under this Agreement or (ii) to have all or part of its rights and benefits under this Agreement, in each case without the prior written consent of (x) the Company, in the case of the Purchaser, and (y) the Purchaser, in the case of the Company, provided that the Purchaser may, without the prior written consent of the Company, assign its rights under this Agreement, including, without limitation, its rights under Section 8 and Section 10.7 above to its general partner or limited partners that are affiliates of the Purchaser in connection with a bona fide distribution in-kind of the Notes, Warrants and/or Underlying Shares acquired by the Purchaser (the “In-kind Distribution”). In the event of any assignment in accordance with the terms of this Agreement, the assignee shall specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject to the provisions of this Agreement and shall deliver an executed counterpart signature page to this Agreement and, notwithstanding such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder from its obligations or liability pursuant to this Agreement. For the avoidance of doubt, any In-kind distribution or transfer to an Affiliate of the Purchaser shall not require the Company’s consent; any In-kind Distribution or transfer to a person that is not an Affiliate of the Purchaser shall constitute a transfer subject to the Company’s prior written consent in accordance with Section 1.2 (such consent not to be unreasonably withheld, conditioned or delayed), and any permitted transferee shall assume all obligations under this Agreement.
15. Severability
15.1 If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.
| 15 |
16. Entire Agreement
16.1 Except as expressly provided in this Agreement and in the agreements, instruments and other documents contemplated or provided for herein, this Agreement contains the entire agreement between the parties with respect to the sale of the Securities and there are no other terms, conditions, representations or warranties, whether expressed, implied, oral or written, by statute or common law, by the Company or by anyone else.
17. Notices
17.1 All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next Business Day. Notices to the Purchaser shall be directed to the email address on the signature page of this Agreement (or such other email address that may be provided by the Purchaser to the Company from time to time) and notices to the Company shall be directed to it at the email address listed below (or such other email address that may be provided by the Company to the Purchaser from time to time):
Company: SuperX AI Technology Limited
Address: 30 Pasir Panjang Rd, #06-31 Mapletree Business City II, Singapore 117440
Attention: Yu Chun Kit, Director
Email Address: anderson@superx.sg
18. Counterparts and Electronic Means
18.1 This Agreement may be executed in any number of counterparts, each of which, when so executed and delivered, shall constitute an original and all of which together shall constitute one instrument. Delivery of an executed copy of this Agreement by electronic facsimile transmission or other means of electronic communication capable of producing a printed copy will be deemed to be execution and delivery of this Agreement as of the date hereinafter set forth.
19. Amendment and Waiver
19.1 No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by the Company and each Purchaser or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right.
20. Public Statements or Releases
20.1 Except as set forth in Section 10.3, neither the Company nor any Purchaser shall make any public announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent of the other party (which consent shall not be unreasonably withheld). Notwithstanding the foregoing, and subject to compliance with Section 10.3, nothing in this Section 20.1 shall prevent any party from making any public announcement it considers necessary in order to satisfy its obligations under the law, including applicable securities laws, or under the rules of any national securities exchange or securities market, in which case the Company shall allow the Purchaser reasonable time to comment on such release or announcement in advance of such issuance, and the Company will consider in good faith any Purchaser comments. The Company shall not include the name of any Purchaser in any press release or public announcement (which, for the avoidance of doubt, shall not include any filing with the SEC if so required by the applicable rules of the SEC) without the prior written consent of such Purchaser, except as otherwise required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company shall allow the Purchaser, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding anything to the contrary in this Section 20.1, Purchaser review shall not be required for Company disclosures that are substantially consistent with prior Company disclosures.
| 16 |
21. Indemnification
21.1 The Company agrees to indemnify and hold harmless each Purchaser and its affiliates, and their respective directors, officers, trustees, members, managers, employees, investment advisors and agents (collectively, the “Indemnified Persons”), from and against any direct losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject solely to the extent arising out of or resulting from a material breach of any representation, warranty, covenant or agreement made by or to be performed on the part of the Company under this Agreement, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts are not resulted from such Person’s fraud or willful misconduct. The Company’s aggregate liability under this Section 21.1 shall not exceed an amount equal to the aggregate Subscription Proceeds payable by the Purchaser; provided that such limitation shall not apply in the case of the Company’s fraud or willful misconduct, .or in the case of any breach of the Company’s representations and warranties as to its corporate existence and authority, the due authorization and valid issuance of the Notes, Warrants and Underlying Shares, or the availability of an exemption from registration under the Securities Act Except with respect to amounts actually paid or payable to a third party in connection with a claim, action, suit or proceeding brought or asserted by such third party (a “Third-Party Claim”) for which a party is entitled to indemnification under this Section 21, neither the Company nor the Purchaser shall be liable to the other party for any special, consequential, punitive or indirect damages under this Section 21.1.
21.2 Any person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified party in respect of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement.
22. Termination
22.1 The obligations of the Company, on the one hand, and the Purchaser, on the other hand, to effect the Closing shall terminate with an immediate effect upon the occurrence of any of the following events:
| (a) | Upon the mutual written consent of the Company and the Purchaser prior to the Closing; |
| (b) | By the Company if any of the conditions with respect to the Purchaser set forth in Section 5.1 shall have become incapable of fulfillment, and shall not have been waived by the Company; |
| (c) | By either party upon providing written notice of termination to the other party within twenty Business Days following the date of this Agreement; |
| (d) | By the Purchaser if any of the conditions set forth in Section 5.2 shall have become incapable of fulfillment, and shall not have been waived by the Purchaser; or |
| (e) | If the Closing has not occurred on or prior to the twentieth Business Day following the date of this Agreement, automatically without any further action by either party, unless the parties agree in writing to amend the Closing Date. |
22.2 In the event of termination of this Agreement pursuant to Section 22.1, this Agreement shall forthwith become null and void and have no effect, without any liability on the part of any party; provided that (i) no such termination shall relieve any party of any liability or damages resulting from any fraud or willful misconduct; and (ii) Sections 11, 12 and 21 hereof shall survive any termination of this Agreement.
[SIGNATURE PAGES TO FOLLOW]
| 17 |
IN WITNESS WHEREOF the Purchaser has duly executed this Agreement as of the date first written above.
| Purchaser: | ||
| Mercuria Holdings (Singapore) Pte. Ltd. | ||
| By: | /s/ Jin Han | |
| Name: | Jin Han | |
| Title: | Mercuria Group Board Member/ Founding Member and Asia CEO | |
USD 26,895,000
(Amount of Subscription / Principal Amount of Notes) (USD)
3,300,000 / 1,100,000
(Number of Ordinary Shares Issuable upon Conversion of Notes) / (Number of Ordinary Shares Issuable upon Exercise of Warrants)
Notice Information:
Address: 12 Marina View, Asia Square Tower 2, #26-01, Singapore 018961
Attention: Jason Jianyun Sun
Email: jasonsun@mercuria.com
IN WITNESS WHEREOF the Company has duly executed this Agreement as of the date first written above.
| Company: | ||
| SUPERX AI TECHNOLOGY LIMITED | ||
| By: | /s/ Jie Yang | |
| Name: | JIE YANG | |
| Title: | Director | |
| 18 |
Exhibit A
Form of Selling Shareholder Representation Letter for Legend Removal
[Date]
[COUNSEL PROVIDING 144 OPINION]
The undersigned (the “Holder”), with an address and telephone number as set forth on the signature page hereto, proposes to sell up to [–] ordinary shares, with with no par value (the “Shares”), of SuperX AI Technology Limited (the “Company”) under Rule 144 promulgated under the Securities Act of 1933, as amended (the “Securities Act”). In order to induce [–] (the “Firm”) to render its legal opinion and enable the Company’s transfer agent to issue the Shares without restrictive legend, the Holder hereby represents and warrants to the Firm as follows:
| (1) | The Holder had no intention of selling, distributing, transferring or otherwise disposing of any such Shares on the original issuance date. |
| (2) | To the extent the Shares were acquired upon conversion of the Notes, the Holder has held the rights to such Shares for at least six (6) months, full consideration for such Shares having been given upon issuance of the Notes (the Closing Date), and the holding period therefor is deemed to have commenced on the Closing Date pursuant to Rule 144(d)(3)(ii). To the extent the Shares were acquired upon exercise of the Warrants, the Holder has held such Shares for at least six (6) months following the date of exercise and payment of the exercise price therefor. |
| (3) | The Holder is familiar with and has carefully reviewed and understands Rule 144 and does not have any reason to believe that the proposed sale of the Shares would not comply with Rule 144. The Holder understands that its broker/bank and the attorney providing the legal opinion regarding its eligibility to sell these shares using the Rule 144 exemption will rely upon its statements herein. If any such statements become inaccurate or incomplete, the Holder will immediately notify its broker/bank and the attorney providing the opinion. The Holder is not now and has not been during the three (3) months preceding the date of this letter, an officer, a director or more than 10% shareholder of the Company or in any other way “affiliate” of the Company, as such term is defined in Rule 144(a)(1). |
| (4) | Without limiting the foregoing, Holder, either alone or in concert with any person, does not directly or indirectly have the ability to control the Company. |
| (5) | The issuance of the Shares without a restrictive legend is not part of a plan or scheme to evade the registration requirements of the Securities Act. The sale of the Shares following the removal of the legend is not in connection with a distribution of securities on behalf of the Company or an affiliate of the Company. |
| 19 |
| (6) | The Holder understands that Rule 144(i)(2) requires that a “shell company” (as defined herein) cease being a shell, notify the Securities and Exchange Commission (“SEC”) that it is no longer a shell company, file information similar to that contained in a Form 10 registration statement with the SEC, and filed its Required Reports (as defined herein) with the SEC for twelve (12) months thereafter. Holder has no reason to believe that the Company is a “shell company”, or if at one time a shell company, that the Company has not fully complied with Rule 144(i)(2). Rule 405 of the Securities Act defined a “shell company” as a company that (i) has no or nominal operations and (ii) either (A) no or nominal assets, (B) assets consisting solely of cash and cash equivalents; or (C) assets consisting of any amount of cash and cash equivalents and nominal other assets. “Required Reports” mean all reports and other materials required by Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), as applicable, other than Form 8-K reports. |
| (7) | The Holder (including, where Holder is an entity, its officer, director and affiliate) is not aware of any material, non-public information about the Company and if, at any time before Holder sells the Shares, Holder acquires such information, Holder will refrain from making any sales of the Shares as long as Holder is in possession of such non-public information. |
| (8) | In the event that the Company ceases to be a reporting company or fails to comply with the periodic reporting requirements pursuant to the Exchange Act, as required by paragraph (i)(2) of Rule 144, and the Shares have not been sold by that time, the Holder will return the unlegended certificates for the Shares to the Company’s transfer agent to have a restricted legend placed on them and will agree to the placement of transfer restriction on such Shares. |
| (9) | The Holder understands that the Firm will fully and solely rely on Holder’s statements herein in rendering its legal opinion, and expressly permits the Firm to fully and solely rely on this representation letter. Holder will indemnify the Firm and its partners, agents and representatives, and hold the Firm and its partners, agents and representatives, harmless from and against all loss, damage, claim, liability and expense (including attorneys’ fees) arising out of, or resulting from, the breach of any representation, warranty or covenant contained herein, or any violation of the Securities Act, Exchange Act, or any other applicable laws or regulations by Holder or by anyone acting on Holder’s behalf. |
| (10) | The Holder has not made, and will not make, any payment in connection with the sale of the Shares to any person other than its broker. The Holder has not solicited or arranged for the solicitation of orders to buy in anticipation of or in connection with my proposed sale of the Shares. |
| (11) | The Holder has the intention to sell the Shares upon receiving confirmation that the Shares would not have a restrictive legend. |
[Signature Page Follows]
| 20 |
Holder Name: [–]
Signature of Authorized Signatory of the Holder:
Authorized Signatory: [NAME], [Director] of [–]
Address: [–]
Date: [–], 2026
| 21 |
Exhibit B
Form of Company Certificate for Legend Removal
SuperX AI Technology Limited
30 Pasir Panjang Road
#06-31, Mapletree Business City
Singapore 117440
[–], 2026
I, the undersigned, DO HEREBY CERTIFY that I am authorized to execute this Officer’s Certificate (the “Certificate”) on behalf of SuperX AI Technology Limited, a British Virgin Islands company (the “Company”) and that:
| (1) | The Company is and has been, for a period of at least ninety (90) days immediately prior to the date hereof, subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). |
| (2) | The Company has filed all reports and other materials required by Section 13 or 15(d) of the Exchange Act, other than Form 8-K reports (the “Required Reports”) during the twelve (12) months preceding the date hereof. |
| (3) | The Company has submitted electronically every Interactive Data File (defined under the Regulation ST) required to be submitted under the rules of interactive data file submissions under the Regulation ST, during the twelve (12) months preceding the date hereof. |
| (4) | The Company is not and has never been a “shell” company as defined in Rule 405 of the Securities Act of 1933 (“Securities Act”), or if at one time a shell company, has ceased being a shell, notified the Securities and Exchange Commission (“SEC”) that it is no longer a shell company, filed information similar to that contained in a Form 10 registration statement with the SEC, and filed its Required Reports (as defined herein) with the SEC for twelve (12) months thereafter, as more fully set forth in Rule 144(i)(2). |
| (5) | [–] (the “Shareholder”) is not an “affiliate” of the Company, as such term is defined in Rule 144(a)(l) and has not been during the preceding three months the date hereof, an officer, director or more than 10% shareholder of the Company or in any way an “affiliate” of the Company, as such term is defined in Rule 144(a)(1). Without limiting the foregoing, the Shareholder, either alone or in concert with any person, does not directly or indirectly have the ability to control the Company. |
| (6) | The Shareholder proposes to sell up to [–] ordinary shares, with no par value (the “Shares”), of the Company. To the extent the Shares were acquired upon conversion of the Notes, the Shareholder has held the rights to such Shares for at least six (6) months, full consideration for such Shares having been given upon issuance of the Notes (the Closing Date), and the holding period therefor is deemed to have commenced on the Closing Date pursuant to Rule 144(d)(3)(ii). To the extent the Shares were acquired upon exercise of the Warrants, the Shareholder has held such Shares for at least six (6) months following the date of exercise and payment of the exercise price therefor. |
| (7) | Issuance of the Shares without a restrictive legend is not part of a plan or scheme to evade the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). Further, the sale of the Shares is not in connection with a distribution of securities on behalf of the Company or an affiliate of the Company. |
[Signature Page Follows]
| 22 |
| SuperX AI Technology Limited | ||
| Signature: | ||
| Name: | ||
| Title: | Executive Director | |
| Address: | 30 Pasir Panjang Road, #06-31 Mapletree Business City II, Singapore 117440 | |
| Date: | [–], 2026 | |
| 23 |
Exhibit C
Form of Purchaser Warrant
FORM OF PURCHASER’S WARRANT
(conformed to the Convertible Note and Warrant Subscription Agreement)
1. Purchaser’s Warrant.
THIS CERTIFIES THAT, pursuant to that certain Convertible Note and Warrant Subscription Agreement by and between SuperX AI Technology Limited (NASDAQ: SUPX), a British Virgin Islands company (the “Company”), and the purchaser identified on the signature page thereto (“the purchaser”), dated [•], 2026 (the “Agreement”), Mercuria or its permitted assignees (each a “Holder”), as the registered owner of this warrant (this “Purchaser’s Warrant”), is entitled, at any time and from time to time during the Exercise Period (as defined below), to subscribe for, purchase and receive up to 1,100,000 ordinary shares of the Company (“Ordinary Shares”; such shares, the “Shares”), being the number of Warrants determined in accordance with the Warrant Coverage Ratio set out in the Agreement, subject to adjustment as provided in Section 6 hereof. This Purchaser’s Warrant shall be issued only on the Warrant Issuance Date (as defined in the Agreement, being the date on which all of the Notes are converted in full) and shall be exercisable during the period commencing on the Warrant Issuance Date and ending at 5:00 p.m., Eastern Time, on the date that is two (2) years after the Warrant Issuance Date (the “Expiration Date”, and such period, the “Exercise Period”), but not thereafter. This Purchaser’s Warrant is exercisable at USD 8.15 per share; provided, however, that upon the occurrence of any of the events specified in Section 6, the rights granted hereby, including the exercise price per share and the number of Ordinary Shares to be received upon exercise, shall be adjusted as therein specified. No cashless or net exercise option shall be available under this Purchaser’s Warrant. The term “Exercise Price” shall mean USD 8.15 per share or the adjusted exercise price resulting from the events set forth in Section 6. Capitalized terms not defined herein have the meanings given in the Agreement.
2. Exercise.
2.1 Exercise Form; Number of Exercises. In order to exercise this Purchaser’s Warrant, the exercise form attached hereto (the “Exercise Notice”) must be duly executed and delivered to the Company by email, together with this Purchaser’s Warrant and payment of the Exercise Price for the Ordinary Shares being purchased (the “Exercise Shares”) solely in cash by wire transfer of immediately available funds to an account designated by the Company. This Purchaser’s Warrant may be exercised on no more than three (3) occasions in the aggregate during the Exercise Period, and each exercise (whether in whole or in part) shall count as one of the three permitted exercises. If the subscription rights represented hereby are not exercised at or before 5:00 p.m., Eastern Time, on the Expiration Date, this Purchaser’s Warrant shall become void.
| 24 |
2.2 Mechanics of Exercise. (i) Delivery of Shares. The Company shall cause the Exercise Shares to be issued and use commercially reasonable efforts to cause them to be delivered to the Holder (through the Depository Trust Company’s DRS where available and there is an effective registration statement, or otherwise in restricted book-entry form) by the date that is two (2) trading days after the latest of (A) delivery of the Exercise Notice, (B) surrender of this Purchaser’s Warrant (if required), and (C) receipt by the Company of the aggregate Exercise Price (the “Share Delivery Date”). (ii) Delivery of New Warrant. If this Purchaser’s Warrant is exercised in part (and the three-exercise limit has not been reached), the Company shall, upon surrender, deliver a new warrant of like tenor for the unexercised balance. (iii) Rescission Rights. If the Company fails to cause the Exercise Shares to be transmitted by the Share Delivery Date (other than through no fault of the Company), the Holder may rescind such exercise upon written notice within one (1) trading day after the Share Delivery Date, and the Company shall return any Exercise Price paid. (iv) No Fractional Shares; (v) Charges, Taxes and Expenses. No fractional shares shall be issued; issuance shall be made without charge to the Holder for any issue or transfer tax, all of which shall be paid by the Company, and the Company shall pay all transfer agent fees required to satisfy the Share Delivery Date.
2.3 Legend. Each book-entry or certificate for the securities issued upon exercise shall bear the customary restrictive legend(s) required under the Securities Act of 1933, as amended (the “Act”), and applicable securities laws, unless such securities have been registered or are exempt from registration, consistent with the legend-removal mechanics in the Agreement.
3. Transfer.
3.1 Restrictions; Transfer to Affiliates. This Purchaser’s Warrant and the securities issuable upon exercise hereof may be assigned, transferred, pledged or otherwise disposed of to one or more of the Holder’s Affiliates (as defined in the Agreement) without the prior written consent of the Company, provided that the transfer complies with the Act and applicable securities laws and the transferee takes subject to, and agrees in writing to be bound by, the terms of this Purchaser’s Warrant (including the 9.99% beneficial ownership limitation in Section 4) and the Agreement. Any assignment, transfer, pledge, disposition or in-kind distribution to a person that is not an Affiliate of the Holder shall require the prior written consent of the Company (such consent not to be unreasonably withheld, conditioned or delayed) and shall comply with the Act and applicable securities laws (including, where applicable, delivery of an opinion of counsel that the transfer is exempt from registration). Upon any transfer of all or any portion of the Notes prior to the Warrant Issuance Date, the corresponding right to receive Warrants shall transfer together with such Notes in the 3:1 ratio provided in the Agreement.
4. Limitations on Exercise.
4.1 Notwithstanding anything to the contrary herein, the Company shall not effect any exercise, and the Holder shall not have the right to exercise any portion hereof, and any such exercise shall be null and void ab initio, to the extent that immediately prior to or following such exercise the Holder, together with the Attribution Parties, would beneficially own (as determined under Section 13(d) of the Exchange Act) in excess of 9.99% (the “Maximum Percentage”) of the Ordinary Shares outstanding following such exercise. In determining the number of outstanding Ordinary Shares the Holder may rely on the number reflected in the Company’s most recent Form 20-F, Form 6-K or other public filing, a more recent public announcement, or a notice from the Company or its Transfer Agent (the “Reported Outstanding Share Number”); upon request, the Company shall within one business day confirm in writing the number then outstanding. If an Exercise Notice would cause the Holder, together with the Attribution Parties, to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of shares to be purchased (the “Reduction Shares”), and the Company shall return any Exercise Price paid for the Reduction Shares as soon as reasonably practicable. Any Ordinary Shares issued in excess of the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and cancelled ab initio, the Holder shall have no power to vote or transfer the Excess Shares, and the Company shall return the Exercise Price paid for the Excess Shares as soon as reasonably practicable. By written notice to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 19.99% specified in such notice; provided that any increase will not be effective until the 61st day after such notice is delivered to the Company and shall not affect any partial exercise effected prior to such change.
| 25 |
4.2 This Section 4 shall not restrict the number of Ordinary Shares the Holder or the Attribution Parties may receive in connection with any adjustment under Section 6. No prior inability to exercise shall affect any subsequent determination of exercisability. This limitation may not be waived and shall apply to any successor holder.
4.3 Attribution Parties. For purposes of this Section 4, “Attribution Parties” means, collectively: (i) any direct or indirect affiliates of the Holder; (ii) any investment vehicle, including any funds, feeder funds or managed accounts, directly or indirectly managed or advised by the Holder’s investment manager or any of its affiliates or principals; (iii) any person acting as a “group” (within the meaning of Section 13(d) of the Exchange Act) together with the Holder or any Attribution Party; and (iv) any other person whose beneficial ownership would be aggregated with the Holder’s for purposes of Section 13(d). The purpose of the foregoing is to subject the Holder and all Attribution Parties collectively to the Maximum Percentage.
5. New Purchaser’s Warrants.
5.1 Partial Exercise or Transfer. Subject to the three-exercise limit in Section 2.1 and the transfer restrictions in Section 3, this Purchaser’s Warrant may be exercised or (in the case of a transfer to a person that is not an Affiliate, with the Company’s prior written consent) assigned in whole or in part. Upon any permitted partial exercise or assignment, and upon surrender of this Purchaser’s Warrant for cancellation together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and transfer tax, the Company shall deliver to the Holder, without charge, a new warrant of like tenor evidencing the right to purchase the Shares as to which this Purchaser’s Warrant has not been exercised or assigned.
5.2 Lost Certificate. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction or mutilation of this Purchaser’s Warrant and reasonably satisfactory indemnification or a bond, the Company shall execute and deliver a new warrant of like tenor and date.
6. Adjustments.
6.1 Adjustments to Exercise Price and Number of Shares. (6.1.1) Share Dividends; Split-Ups. If the number of outstanding Ordinary Shares is increased by a share dividend payable in Ordinary Shares or by a split-up or similar event, the number of Shares purchasable hereunder shall be proportionately increased and the Exercise Price proportionately decreased. (6.1.2) Aggregation. If the number of outstanding Ordinary Shares is decreased by a reverse split, consolidation, combination or reclassification, the number of Shares purchasable hereunder shall be proportionately decreased and the Exercise Price proportionately increased. (6.1.3) Reorganization. In case of any reclassification or reorganization (other than as covered above), or any share reconstruction, amalgamation or consolidation of the Company with or into another entity, or any sale of all or substantially all of the Company’s property in connection with which the Company is dissolved, the Holder shall thereafter have the right (until expiration of the Exercise Period), upon exercise and for the same aggregate Exercise Price, to receive the kind and amount of shares, other securities or property (including cash) receivable upon such event by a holder of the number of Ordinary Shares obtainable upon exercise immediately prior to such event.
| 26 |
6.2 Substitute Warrant. In case of any consolidation, share reconstruction or amalgamation of the Company with or into another entity that results in a reclassification or change of the outstanding Ordinary Shares, the successor entity shall execute and deliver to the Holder a supplemental warrant providing the right to receive, upon exercise, the kind and amount of shares, other securities and property receivable upon such event by a holder of the number of Ordinary Shares for which this Purchaser’s Warrant might have been exercised immediately prior thereto, with adjustment provisions substantially the same as those in this Section 6.
6.4 Notice to Holder. Whenever the Exercise Price is adjusted, the Company shall promptly provide the Holder with notice setting forth the adjusted Exercise Price, any resulting adjustment to the number of Shares, and a brief statement of the facts requiring the adjustment. The Company shall also provide the Holder at least ten (10) days’ prior written notice of any record or effective date for any dividend or distribution, redemption, grant of rights or warrants, reclassification, consolidation, merger, sale of all or substantially all assets, compulsory share exchange, or dissolution, liquidation or winding-up; provided that no separate notice need be given to the extent the Company has made a public announcement or compliant filing with the Commission.
7. Reserved.
8. Certain Notice Requirements.
8.1 / 8.2. If any of the events described below occurs prior to the expiration and exercise of this Purchaser’s Warrant, the Company shall give the Holder written notice at least fifteen (15) days prior to the applicable record or transfer-book closing date; if not otherwise available on EDGAR, the Company shall deliver to the Holder a copy of each notice given to its other shareholders at the same time and in the same manner. The events requiring notice are: (i) a record date for a non-cash dividend or distribution (or a cash dividend other than out of retained earnings); (ii) an offer to all holders of Ordinary Shares of additional shares or convertible/exchangeable securities or rights; (iii) any reclassification, consolidation or merger requiring shareholder approval, or any compulsory share exchange; or (iv) a dissolution, liquidation or winding-up, or a sale of all or substantially all of the Company’s assets.
9. Miscellaneous.
9.5 Governing Law; Submission to Jurisdiction; Trial by Jury. This Purchaser’s Warrant shall be governed by and construed in accordance with the internal laws of the State of New York, without regard to conflict-of-laws principles. Any action arising out of or relating to this Purchaser’s Warrant shall be brought exclusively in the courts of the State of New York or the United States District Court for the Southern District of New York, and the Company irrevocably submits to such exclusive jurisdiction and waives any objection thereto. The prevailing party(ies) in any such action shall be entitled to recover from the other party(ies) all of their reasonable attorneys’ fees and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company and the Holder each irrevocably waive, to the fullest extent permitted by law, any right to trial by jury in any proceeding arising out of or relating to this Purchaser’s Warrant.
9.7 Holder Not Deemed a Shareholder; Other. Except as otherwise provided herein, the Holder, solely in its capacity as such, shall not be entitled to vote or receive dividends or be deemed a holder of share capital of the Company prior to the issuance of the Exercise Shares upon due exercise. The Company and the Holder may amend this Purchaser’s Warrant to cure any ambiguity or correct any defective or inconsistent provision (provided it does not adversely affect the Holder); all other modifications require the written consent of the party against whom enforcement is sought. This Purchaser’s Warrant and the Agreement constitute the entire agreement of the parties with respect to the subject matter hereof.
[Signature page follows]
| 27 |
IN WITNESS WHEREOF, the Company has caused this Purchaser’s Warrant to be signed by its duly authorized officer as of the [*] day of [*] 2026.
| SUPERX AI TECHNOLOGY LIMITED | ||
| By: | ||
| Name: | ||
| Title: | Executive Director | |
| Accepted By: | ||
| By: | ||
| Name: | ||
| Title: | ||
[Signature Page to Form of Purchaser Warrant]
| 28 |
EXHIBIT A
Exercise Form
Form to be used to exercise Purchaser’s Warrant:
Date: , 202_
The undersigned hereby elects irrevocably to exercise the Purchaser’s Warrant for Ordinary Shares of SuperX AI Technology Limited, a British Virgin Islands exempted company (the “Company”), and hereby makes payment of $ (at the rate of $ per share) in payment of the Exercise Price pursuant thereto. Please issue the Ordinary Shares as to which this Purchaser’s Warrant is exercised in accordance with the instructions given below and, if applicable, a new Purchaser’s Warrant representing the number of Ordinary Shares for which this Purchaser’s Warrant has not been exercised.
Signature:
Signature Guaranteed:
INSTRUCTIONS FOR REGISTRATION OF SECURITIES
Name:
(Print in Block Letters)
Address:
(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
| 29 |
Schedule I
Scope of BVI Closing Legal Opinion
| 1. | The Company is a company duly incorporated with limited liability under the BVI Business Companies Act, 2004, and is validly existing and in good standing under the laws of the British Virgin Islands. |
| 2. | The Company has the corporate power to execute and deliver this Agreement and perform its obligations thereunder. |
| 3. | The Company has duly authorized, executed and delivered this Agreement, and this Agreement constitutes its valid and binding obligations enforceable against it in accordance with their terms. |
| 4. | The Notes and the Warrants to be issued by the Company under this Agreement have been duly authorized and, when executed, issued and delivered against payment therefor in accordance with this Agreement, will constitute valid and binding obligations of the Company; and the Underlying Shares issuable upon conversion of the Notes or exercise of the Warrants have been duly authorized and reserved for issuance and, when issued and delivered upon such conversion or exercise (and, in the case of the Warrants, against payment of the exercise price therefor) in accordance with the terms of the Notes, the Warrants and this Agreement, will be validly issued, fully paid and non-assessable. |
| 5. | The execution and delivery of this Agreement by the Company, the performance by the Company of its obligations under this Agreement do not contravene: |
| – | any provision of the Company’s M&AA; or |
| – | any law, regulation or order of the British Virgin Islands applicable to the Company. |
| 6. | No consents, licences, approvals, authorisations or exemptions of any governmental or regulatory authority, agency or court in the British Virgin Islands are required by the Company (other than those already obtained by the Company) in connection with the execution of this Agreement by the Company or the exercise of its rights or the performance by it of its obligations thereunder. |
| 7. | Upon the entry of the relevant holder’s name in the Company’s register of members as the holder of the Underlying Shares (following conversion of the Notes or exercise of the Warrants) in accordance with the Company’s M&AA, such entry will constitute prima facie evidence under the BVI Business Companies Act that such holder holds legal title to such Underlying Shares. There is no provision of BVI law that would impose any general restriction on the transfer of the Underlying Shares. |
| 8. | The express choice of the laws of the jurisdiction specified in this Agreement to be the governing law of this Agreement will be recognised and applied by the courts of the British Virgin Islands in any action brought in such courts in respect of this Agreement. |
| 30 |
Schedule II
Scope of US Closing Legal Opinion
| 1. | Based upon and subject to the accuracy of the representations, warranties and covenants of the Company and the Purchaser contained in this Agreement, the offer and sale of the Securities to the Purchaser pursuant to this Agreement are not required to be registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption from the registration requirements of the Securities Act provided by Regulation S promulgated thereunder. We express no opinion with respect to any subsequent resale or distribution of the Securities or the Underlying Shares. We express no opinion as to the securities laws of any U.S. state or any “blue sky” laws. |
| 2. | The execution and delivery of this Agreement by the Company, the performance by the Company of its obligations under this Agreement do not contravene any law or regulation of the State of New York and the United States that is known to be customarily applicable to transactions of this nature. |
| 3. | No consent, approval, authorization or order of, or filing with, any U.S. federal or New York governmental authority is required for the execution and delivery by the Company of this Agreement, or the performance by the Company of its obligations thereunder, other than (i) those required under U.S. federal or state securities laws (as to which we express no opinion except as expressly set forth herein), and (ii) those consents, approvals, authorizations or orders that, if not obtained or made, would not reasonably be expected to have a material adverse effect on the Company’s ability to perform its obligations under this Agreement. |
| 4. | As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable requirements of the Exchange Act and the applicable rules and regulations of the SEC thereunder (in each case other than the financial statements and schedules and other company and financial data included or incorporated by reference therein, as to which we express no opinion). |
| 5. | As of the date of this Agreement, to our knowledge, there is no suit, action, proceeding or investigation pending or, threatened against the Company by Nasdaq, the SEC or any other securities regulator to prohibit or terminate the listing of the Ordinary Shares on Nasdaq or to deregister the Ordinary Shares under the Exchange Act. The Company is not, and immediately after receipt of the Subscription Proceeds payable under this Agreement, will not be, an “investment company” within the meaning of the U.S. Investment Company Act of 1940, as amended. |
| 6. | The Company is a “foreign private issuer” within the meaning of Rule 405 under the Securities Act and a “foreign issuer” (as defined in Rule 902(e) of Regulation S) and reasonably believes that there is no “substantial U.S. market interest” (as defined in Rule 902(j) of Regulation S) in any of the Securities. |
| 31 |
Schedule III
Additional Representations and Warranties of the Company
| 1. | Capitalization. The Company’s disclosure of its authorized, issued and outstanding share capital in the SEC Reports containing such disclosure was accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding Ordinary Shares have been duly authorized and validly issued and are fully paid and non-assessable, and will not be subject to any call for further capital. None of the outstanding share capital of the Company was issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been waived, and all such share capital was issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties. Except as disclosed in the SEC Reports or pursuant to the Company’s equity incentive plans or outstanding warrants described in the SEC Reports, there are no outstanding rights (including, without limitation, preemptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any share capital or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any share capital of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the share capital of the Company conforms in all material respects to the description thereof contained in the SEC Reports; and all the outstanding share capital or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable (except, in the case of any foreign subsidiary, for directors’ qualifying shares), are not subject to any call for further capital and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party, except as disclosed in the SEC Reports. |
| 2. | Registration Rights. Except as set forth in this Agreement or as disclosed in the SEC Reports, the Company is presently not under any obligation, and has not granted any rights, to register under the Securities Act any of the Company’s presently outstanding securities, other than such rights and obligations that have expired or been satisfied or waived. |
| 3. | SEC Filings; Financial Statements. |
| (a) | The Company has filed all forms, statements, certifications, reports and documents required to be filed by it with the SEC under Section 13 and 15(d) of the Securities Exchange Act of 1934, as amended, and all of the rules and regulations promulgated thereunder (the “Exchange Act”) for the one year preceding the date of this Agreement. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable requirements of the Exchange Act, and, as of the time they were filed, none of the filed SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC staff with respect to the SEC Reports. To the Company’s knowledge, none of the SEC Reports are the subject of an ongoing SEC review. The interactive data in eXtensible Business Reporting Language included in the SEC Reports fairly presents the information called for in all material respects and has been prepared in accordance with the SEC’s rules and guidelines applicable thereto. The Company is not, and has never been, an issuer subject to Rule 144(i) under the Securities Act. |
| 32 |
| (b) | The consolidated financial statements of the Company included in the SEC Reports (collectively, the “Financial Statements”) comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and fairly present in all material respects the consolidated financial position of the Company and its subsidiaries as of the dates indicated, and the results of its operations and cash flows for the periods therein specified, and have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods therein specified (except as otherwise noted therein, and except that any unaudited financial statements may not contain certain footnotes and are subject to normal and recurring year-end adjustments). Except as set forth in the Financial Statements filed prior to the date of this Agreement, or as otherwise disclosed in the SEC Reports, the Company has not incurred any liabilities, contingent or otherwise, except (i) those incurred in the ordinary course of business, consistent with past practices since the date of such financial statements or (ii) liabilities not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. |
| 4. | Absence of Changes. Since June 30, 2025, except as disclosed in the SEC Reports (a) the Company has conducted its business only in the ordinary course of business and there have been no material transactions entered into by the Company or any of its subsidiaries other than in the ordinary course of business (except for the execution and performance of this Agreement and the discussions, negotiations and transactions related thereto); (b) no material change to any material contract or arrangement by which the Company or any of its subsidiaries is bound or to which any of its assets or properties is subject has been entered into that has not been disclosed in the SEC Reports; and (c) there has not been any other event or condition of any character that has had or would reasonably be expected to have a Material Adverse Effect; provided, however, that none of the following will be deemed in themselves, either alone or in combination, to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material Adverse Effect under this Section 4: |
| (i) | any change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States, Hong Kong or any other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby; |
| (ii) | general financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the Company is not disproportionately affected thereby; |
| (iii) | any change that generally affects industries in which the Company and its subsidiaries conduct business, provided that the Company is not disproportionately affected thereby; |
| (iv) | earthquakes, hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, including the COVID-19 pandemic and related strains, epidemic or similar health emergency, and other force majeure events in the United States, Hong Kong or any other location, provided that the Company is not disproportionately affected thereby; |
| (v) | national or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected thereby; |
| (vi) | material changes in laws after the date of this Agreement; and |
| (vii) | in and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses, earnings or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances giving rise to such failure may be deemed to constitute, and may be taken into account in determining whether there has been, a Material Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(v) of this definition). |
| 5. | Absence of Litigation. Except as disclosed in the SEC Reports, there is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry pending or, to the Company’s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments or decrees outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that have had or would reasonably be expected to have a Material Adverse Effect. Except as disclosed in the SEC Reports, neither the Company nor any subsidiary, nor to the knowledge of the Company, any director or officer of the Company or any subsidiary, is presently, or since June 30, 2025 has been, the subject of any action involving a claim of violation of or liability under federal, state or foreign securities laws relating to the Company or such subsidiary or a claim of breach of fiduciary duty relating to the Company or such subsidiary. |
| 33 |
| 6. | Compliance with Law; Permits. Except as disclosed in the SEC Reports, neither the Company nor any of its subsidiaries is in violation of, or has received any written notices of violations with respect to, any laws, statutes, ordinances, rules or regulations of any governmental body, court or government agency or instrumentality, except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have, to the extent required by applicable law, all required licenses, permits, certificates and other authorizations (collectively, “Governmental Authorizations”) from such federal, state, local, or foreign government or governmental agency, department or body that are currently necessary for the operation of the business of the Company and its subsidiaries as currently conducted, except where the failure to possess currently such Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. Neither the Company nor any subsidiary has received any written (or, to the Company’s knowledge, oral) notice regarding any revocation or material modification of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, has or would reasonably be expected to result in a Material Adverse Effect. |
| 7. | Intellectual Property. The Company and its subsidiaries own, or have rights to use, all material inventions, patent applications, patents, trademarks, trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented and/or unpatentable proprietary of confidential information, systems or procedures) and other intellectual property as described in the SEC Reports necessary for, or used in the conduct of their respective businesses (including as described in the SEC Reports) (collectively, “Intellectual Property”), except where any failure to own, possess or acquire such Intellectual Property has not had, and would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual Property of the Company and its subsidiaries has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company’s knowledge: (i) there are no third parties who have rights to any Intellectual Property, including no liens, security interests, or other encumbrances; and (ii) there is no infringement by third parties of any Intellectual Property, except, in each case, which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. No action, suit, or other proceeding is pending, or, to the Company’s knowledge, is threatened: (A) challenging the Company’s or its subsidiaries’ rights in or to any Intellectual Property; (B) challenging the validity, enforceability or scope of any Intellectual Property; or (C) alleging that the Company or any of its subsidiaries infringes, misappropriates, or otherwise violates any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, except, in each case, which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or any of its subsidiaries in all material respects, and to the Company’s knowledge all such agreements are in full force and effect. To the Company’s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property. |
| 8. | Employee Benefits. The Company and its subsidiaries are in compliance with all applicable federal, state, local and foreign laws, rules and regulations regarding employment, except for any failures to comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. There is no labor dispute, strike or work stoppage against the Company or its subsidiaries pending or, to the knowledge of the Company, threatened which may interfere with the business activities of the Company, except where such dispute, strike or work stoppage is not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. |
| 9. | Taxes. The Company and its subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax Returns required to have been filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except for those which are being contested in good faith and except where failure to file such Tax Returns or pay such Taxes would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal tax returns has been made against the Company. The charges, accruals and reserves on the books of the Company in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or reassessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect. No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its subsidiaries are presently in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on any of the assets of the Company. At all times since inception, the Company has been and continues to be classified as a corporation for U.S. federal income tax purposes. Neither the Company nor any of its subsidiaries has been a United States real property holding corporation within the meaning of Code Section 897(c)-2 during the period specified in Code Section 897(c)(1)(A)(ii). No stamp duty, stamp duty reserve, registration, transfer or other similar taxes or duties (“Transfer Taxes”) are payable in British Virgin Islands or Hong Kong by or on behalf of the Purchaser in connection with (a) the sale and delivery of the Notes and the Warrants to or for the account of the Purchaser in the manner contemplated by this Agreement or (b) the execution and delivery of this Agreement. |
| 10. | Title. Each of the Company and its subsidiaries has good and marketable title to all personal property owned by it that is material to the business of the Company, free and clear of all liens, encumbrances and defects except such as do not materially and adversely affect the value of such property and do not materially and adversely interfere with the use made and proposed to be made of such property by the Company or its subsidiaries, as the case may be. Any real property and buildings held under lease by the Company or its subsidiaries is held under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or its subsidiaries, as the case may be. The Company does not own any real property. |
| 34 |
| 11. | Insurance. The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased) and tangible assets, and each of such insurance policies is in full force and effect and the Company is in compliance in all material respects with the terms of such insurance policies. Other than customary end-of-policy notifications from insurance carriers, since June 30, 2025, the Company has not received any notice or other communication regarding any actual or possible: (i) cancellation or invalidation of any material insurance policy or (ii) refusal or denial of any coverage, reservation of rights or rejection of any material claim under any insurance policy. |
| 12. | Trading Markets. The issued and outstanding Ordinary Shares are registered pursuant to Section 12(b) of the Exchange Act and are listed for trading on the Nasdaq Capital Market under the symbol “SUPX”. The Company is in compliance with all applicable listing requirements of Nasdaq. As of the date of this Agreement, there is no suit, action, proceeding or investigation pending or, to the knowledge of the Company, threatened against the Company by Nasdaq, the SEC or any other securities regulator to prohibit or terminate the listing of the Ordinary Shares on Nasdaq or to deregister the Ordinary Shares under the Exchange Act. The Company has taken no action as of the date of this Agreement that is designed to terminate the registration of the Ordinary Shares under the Exchange Act. The Ordinary Shares are currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation. |
| 13. | Sarbanes-Oxley Act. The Company is, and since June 30, 2025 has been, in compliance in all material respects with all applicable requirements of the Sarbanes-Oxley Act of 2002 and applicable rules and regulations promulgated by the SEC thereunder. |
| 14. | Accounting Controls and Disclosure Controls and Procedures. The Company maintains a system of internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that is designed to comply with the requirements of the Exchange Act applicable to the Company and provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and procedures sufficient to provide reasonable assurance (i) that the Company maintains records that in reasonable detail accurately and fairly reflect the Company’s transactions and dispositions of assets, (ii) that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, (iii) that receipts and expenditures are made only in accordance with authorizations of management and the Board of Directors of the Company and (iv) regarding prevention or timely detection of the unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the Company’s financial statements. Except as disclosed in the Company’s SEC Reports filed prior to the date of this Agreement, the Company has not identified any material weaknesses in the design or operation of the Company’s internal control over financial reporting. The Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) are designed to provide reasonable assurance that all information (both financial and non-financial) required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and that all such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. |
| 15. | Price Stabilization of Ordinary Shares. The Company has not taken, nor will it take, directly or indirectly, any action designed to stabilize or manipulate the price of the Ordinary Shares in violation of applicable securities laws to facilitate the sale or resale of the Ordinary Shares. |
| 16. | Investment Company Act; Not a Passive Foreign Investment Company. The Company is not, and immediately after receipt of the Subscription Proceeds payable under this Agreement, will not be, an “investment company” within the meaning of the U.S. Investment Company Act of 1940, as amended. As of June 30, 2025, the Company would not have been considered a “passive foreign investment company,” as such term is defined in the Code, and immediately after the offering and sale of the Securities, less than 50% of the Company’s assets will be classified as assets that produce, or are held for the production of, passive income for the purpose of Section 1297 of the Code and the rules, regulations and administrative pronouncements relating thereto, including cash. Neither the Company nor any subsidiary is, and, after giving effect to the offering and sale of the Securities, neither of them will be, a “controlled foreign corporation” as defined by the Code. |
| 35 |
| 17. | General Solicitation; No Integration or Aggregation. Neither the Company nor any other person or entity authorized by the Company to act on its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of investors with respect any offer or sale of the Securities pursuant to this Agreement. The Company has not, directly or indirectly, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which, to its knowledge, is or will be (i) integrated with the offer and sale of the Securities pursuant to this Agreement for purposes of the Securities Act or (ii) aggregated with prior offerings by the Company for the purposes of the rules and regulations of Nasdaq. With respect to those Securities sold in reliance upon Regulation S, (x) none of the Company, its Affiliates or any person acting on its or their behalf has engaged in any directed selling efforts within the meaning of Regulation S and (y) each of the Company and its Affiliates and any person acting on its or their behalf has complied with the offering restrictions set forth in Regulation S. |
| 18. | Brokers and Finders. Neither the Company nor any other person authorized by the Company to act on its behalf has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement. |
| 19. | Anti-Bribery and Anti-Money Laundering Laws. Each of the Company, its subsidiaries and, to the knowledge of the Company, any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed December 17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope; (B) anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative to the group or organization continues to concur, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder; or (C) except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect, any laws with respect to import and export control and economic sanctions, including the U.S. Export Administration Regulations, the U.S. International Traffic in Arms Regulations, and economic sanctions regulations and executive orders administered by the U.S. Department of the Treasury Office of Foreign Asset Control. |
| 20. | Cybersecurity. The Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, and are free and clear of all material Trojan horses, time bombs, malware and other malicious code. The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or regulated data (“Confidential Data”) used or maintained in connection with their businesses, and the integrity, availability continuous operation, redundancy and security of all IT Systems. |
| 21. | Transactions with Affiliates and Employees. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, shareholders, customers or suppliers of the Company, on the other hand, that is required to be described in the SEC Reports that is not so described. |
| 22. | Submission to Jurisdiction. The Company has the power to submit, and pursuant to Section 11 of this Agreement, has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of each United States federal court and New York state court located in the Borough of Manhattan, City of New York in the State of New York, U.S.A. (each, a “New York Court”) and the Company has the power to designate, appoint and authorize, and pursuant to Section 10 of this Agreement, has legally, validly, effectively and irrevocably designated, appointed and authorized an agent for service of process in any action arising out of or relating to this Agreement or the Securities in any New York Court, and service of process effected on such authorized agent will be effective to confer valid personal jurisdiction over the Company as provided in Section 11 hereof. |
| 23. | Foreign Private Issuer. The Company is a “foreign private issuer” within the meaning of Rule 405 under the Securities Act and a “foreign issuer” (as defined in Rule 902(e) of Regulation S) and reasonably believes that there is no “substantial U.S. market interest” (as defined in Rule 902(j) of Regulation S) in any of the Securities. The Company agrees to notify the Purchaser as soon as practicable upon the Company ceasing to be a foreign private issuer. |
| 36 |